Also known as: MMN
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Dianthus Therapeutics will host a conference call on March 9, 2026, to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06537999 |
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy |
ACTIVE_NOT_RECRUITING | PHASE2 |
